Examination of the TPMT and NUDT15*3 Variants to Predict the Response to Thiopurines in an Italian Cohort of Patients with Inflammatory Bowel Disease.

Thiopurines are employed in inflammatory bowel diseases (IBDs; Crohn's disease, CD; ulcerative colitis, UC) to induce remission, prevent relapse, and reduce the steroid dosage, although they can sometimes be ineffective and present side effects. Genetic variations in the and genes are well recognized to influence the therapeutic response, despite notable regional differences in their frequencies across various ethnic populations. Herein, the risk haplotypes TPMT*3A, 3B, 3C, and the variant NUDT153 were examined in a retrospective cohort of 383 Italian IBD patients who received azathioprine or 6-mercaptopurine. and genotyping was performed by Sanger sequencing and TaqMan allelic discrimination, respectively. Allelic and genotype frequencies and genotype-phenotype correlations in non-responder and intolerant patients were assessed in comparison to responders. In total, 17% of patients did not respond to treatment, while 20% experienced adverse events, with leukopenia found in 13% of patients. TPMT haplotypes were found in 3.1% of patients, and 1.6% had the NUDT153 variant. CD patients with leukopenia had a higher frequency of the risk haplotype (40% vs. 4%, = 0.024). Although additional validation through larger prospective studies or meta-analyses is needed, our findings support the importance of gene-variant assessment for forecasting azathioprine-related leukopenia in Italian IBD patients.